Seikagaku reported FY 1Q20 orthopedic revenue of ¥3,029.1 million (USD $28.2 million), -21.2% vs. 1Q19.
The company suffered negative impact from drug price reductions in Japan as well as spreading COVID infections in its key markets of Japan and the U.S. While Seikagaku increased its market share of viscosupplements in Japan, its overall domestic market contracted for the product. Sales of the Gel-One viscosupplement in the U.S. declined due to elective procedure restrictions. While economic activity in China resumed ahead of other regions, Seikagaku’s sales declined due to continued curtailment of outpatient procedures beyond April.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
1Q20
1Q19
$ Chg
% Chg
Orthobiologics
$28.2
$35.7
($7.6)
(21.2%)
Geographic Sales
1Q20
1Q19
$ Chg
% Chg
Domestic (Japan)
$16.5
$16.5
$0.0
0.1%
International
$11.7
$19.3
($7.6)
(39.4%)
Total
$28.2
$35.7
($7.6)
(21.2%)
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Seikagaku reported FY 1Q20 orthopedic revenue of ¥3,029.1 million (USD $28.2 million), -21.2% vs. 1Q19.
The company suffered negative impact from drug price reductions in Japan as well as spreading COVID infections in its key markets of Japan and the U.S. While Seikagaku increased its market share of viscosupplements in Japan, its overall...
Seikagaku reported FY 1Q20 orthopedic revenue of ¥3,029.1 million (USD $28.2 million), -21.2% vs. 1Q19.
The company suffered negative impact from drug price reductions in Japan as well as spreading COVID infections in its key markets of Japan and the U.S. While Seikagaku increased its market share of viscosupplements in Japan, its overall domestic market contracted for the product. Sales of the Gel-One viscosupplement in the U.S. declined due to elective procedure restrictions. While economic activity in China resumed ahead of other regions, Seikagaku’s sales declined due to continued curtailment of outpatient procedures beyond April.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
1Q20
1Q19
$ Chg
% Chg
Orthobiologics
$28.2
$35.7
($7.6)
(21.2%)
Geographic Sales
1Q20
1Q19
$ Chg
% Chg
Domestic (Japan)
$16.5
$16.5
$0.0
0.1%
International
$11.7
$19.3
($7.6)
(39.4%)
Total
$28.2
$35.7
($7.6)
(21.2%)
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
